Compare FLXS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | CNTB |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 157.1M |
| IPO Year | N/A | 2021 |
| Metric | FLXS | CNTB |
|---|---|---|
| Price | $40.78 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 29.9K | ★ 440.3K |
| Earning Date | 02-02-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | ★ 64.53 | N/A |
| EPS | ★ 4.11 | N/A |
| Revenue | ★ $447,505,000.00 | $762,000.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $3.04 | $38,289.22 |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | ★ 6.00 | N/A |
| 52 Week Low | $29.38 | $0.51 |
| 52 Week High | $64.14 | $3.28 |
| Indicator | FLXS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 45.72 |
| Support Level | $41.93 | $2.03 |
| Resistance Level | $42.93 | $2.38 |
| Average True Range (ATR) | 1.04 | 0.17 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 45.86 | 26.79 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.